Literature DB >> 23719787

Natalizumab and the development of extensive brain lesions in neuromyelitis optica.

Maciej Juryńczyk, Krzysztof Zaleski, Krzysztof Selmaj.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23719787     DOI： 10.1007/s00415-013-6965-4

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  12 in total

Review 1.  Conventional brain MRI in neuromyelitis optica.

Authors:  J A Cabrera-Gomez; I Kister
Journal:  Eur J Neurol       Date:  2011-10-31       Impact factor: 6.089

2.  Brain abnormalities in neuromyelitis optica.

Authors:  Jee-Eun Kim; Sung-Min Kim; Suk-Won Ahn; Bung Chan Lim; Jong Hee Chae; Yoon-Ho Hong; Kyung-Seok Park; Jung-Joon Sung; Kwang-Woo Lee
Journal:  J Neurol Sci       Date:  2011-01-13       Impact factor: 3.181

3.  Does natalizumab therapy worsen neuromyelitis optica?

Authors:  Anu Jacob; Michael Hutchinson; Liene Elsone; Siobhan Kelly; Rehiana Ali; Ivars Saukans; Niall Tubridy; Mike Boggild
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

4.  Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.

Authors:  M H Barnett; J W Prineas; M E Buckland; J D E Parratt; J D Pollard
Journal:  Mult Scler       Date:  2011-08-25       Impact factor: 6.312

5.  Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders.

Authors:  S M Magaña; M Matiello; S J Pittock; A McKeon; V A Lennon; A A Rabinstein; E Shuster; O H Kantarci; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2009-02-24       Impact factor: 9.910

6.  Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.

Authors:  Lucy Matthews; Rita Marasco; Mark Jenkinson; Wilhelm Küker; Sebastian Luppe; Maria Isabel Leite; Antonio Giorgio; Nicola De Stefano; Neil Robertson; Heidi Johansen-Berg; Nikos Evangelou; Jacqueline Palace
Journal:  Neurology       Date:  2013-03-13       Impact factor: 9.910

7.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors:  Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal:  Lancet Neurol       Date:  2009-02-07       Impact factor: 44.182

8.  Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

Authors:  M Krumbholz; I Meinl; T Kümpfel; R Hohlfeld; E Meinl
Journal:  Neurology       Date:  2008-10-21       Impact factor: 9.910

9.  Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

Authors:  P Kivisäkk; B C Healy; V Viglietta; F J Quintana; M A Hootstein; H L Weiner; S J Khoury
Journal:  Neurology       Date:  2009-06-02       Impact factor: 9.910

10.  Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

Authors:  Lars Börnsen; Jeppe Romme Christensen; Rikke Ratzer; Annette Bang Oturai; Per Soelberg Sørensen; Helle Bach Søndergaard; Finn Sellebjerg
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240
View more
  8 in total

Review 1.  Neuro-ophthalmology update.

Authors:  Konrad P Weber; Dominik Straumann
Journal:  J Neurol       Date:  2013-09-26       Impact factor: 4.849

Review 2.  Neuromyelitis Optica (Devic's Syndrome): an Appraisal.

Authors:  Teresa M Crout; Laura P Parks; Vikas Majithia
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

3.  Evaluation of aquaporin-4 antibody assays.

Authors:  Patrick J Waters; Sean J Pittock; Jeffrey L Bennett; Sven Jarius; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Clin Exp Neuroimmunol       Date:  2014-04-22

Review 4.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

5.  Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.

Authors:  Maciej Juryńczyk; Brian Weinshenker; Gulsen Akman-Demir; Nasrin Asgari; David Barnes; Mike Boggild; Abhijit Chaudhuri; Marie D'hooghe; Nikos Evangelou; Ruth Geraldes; Zsolt Illes; Anu Jacob; Ho Jin Kim; Ingo Kleiter; Michael Levy; Romain Marignier; Christopher McGuigan; Katy Murray; Ichiro Nakashima; Lekha Pandit; Friedemann Paul; Sean Pittock; Krzysztof Selmaj; Jérôme de Sèze; Aksel Siva; Radu Tanasescu; Sandra Vukusic; Dean Wingerchuk; Damian Wren; Isabel Leite; Jacqueline Palace
Journal:  J Neurol       Date:  2015-11-03       Impact factor: 4.849

Review 6.  Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices.

Authors:  I-Jun Chou; Huei-Shyong Wang; William P Whitehouse; Cris S Constantinescu
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

7.  Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.

Authors:  Anna Gahlen; Anne-Kathrin Trampe; Steffen Haupeltshofer; Marius Ringelstein; Orhan Aktas; Achim Berthele; Brigitte Wildemann; Ralf Gold; Sven Jarius; Ingo Kleiter
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-06-16

8.  Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report.

Authors:  De-Hyung Lee; Alexandra B Laemmer; Anne Waschbisch; Tobias Struffert; Christian Maihöfner; Stefan Schwab; Ralf Andreas Linker
Journal:  J Med Case Rep       Date:  2014-05-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.